Filing Flows › Cytokinetics (CYTK) › Q2 2026 › vs Q2 2025
Cytokinetics (CYTK) Q2 2026 vs Q2 2025 (year over year)
Cytokinetics's revenue fell $38.1M (-57%) from $66.8M in Q2 2025 to $28.6M in Q2 2026. The biggest changes: Net Product Revenue +$25.3M (—); Collaboration Revenues +$874K (+36%).
Cytokinetics, Q2 2026: revenue $28.6M (-57% year over year), operating margin -626.0%, net loss $199M, operating cash flow −$160M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Net Product Revenue | $25.3M | $0 | $25.3M | — |
| Collaboration Revenues | $3.3M | $2.4M | $874K | +36% |
| Revenue | $28.6M | $66.8M | −$38.1M | -57% |
| Net loss | $199M | $134M | $64.4M | +48% |
| Costs & expenses | $227M | $201M | $26.2M | +13% |
| Operating costs | $208M | $178M | $29.5M | +17% |
| Interest & other, net | $19.6M | $22.9M | −$3.3M | -14% |
| Research & development | $97.8M | $110M | −$12.3M | -11% |
| SG&A | $104M | $65.7M | $38.7M | +59% |
| Other operating costs | $5.6M | $2.4M | $3.2M | +131% |
| Operating cash sources | $199M | $158M | $41.1M | +26% |
| Depreciation & amortization | $3.6M | $2.3M | $1.3M | +59% |
| Share-based compensation | $35.7M | $27.5M | $8.2M | +30% |
| Cash used in operations | $160M | $128M | $31.6M | +25% |
| Net loss absorbed | $199M | $134M | $64.4M | +48% |
| Working capital & other | $420K | $23.7M | −$23.3M | -98% |
Questions
How much did Cytokinetics's revenue grow year over year in Q2 2026?
Cytokinetics's revenue fell $38.1M (-57%) from $66.8M in Q2 2025 to $28.6M in Q2 2026.
What drove Cytokinetics's revenue change in Q2 2026?
Net Product Revenue +$25.3M (—); Collaboration Revenues +$874K (+36%).